Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
The Hain Celestial Group, Inc. ( NASDAQ: HAIN) Q2 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Alexis Tessier - VP, IR Wendy Davidson - President & CEO Lee Boyce - CFO ...
GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...
Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
SHOPPING: Shoppers are turning to Calocrub Supplements for faster, more effective weight loss claiming it's better than ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback